RESEARCH TRIANGLE PARK, N.C., May 11 /PRNewswire-FirstCall/ -- Incara Pharmaceuticals Corporation (BULLETIN BOARD: ICRA) announced that Richard E. Gammans, Ph.D., Executive Vice President of Incara is scheduled to present at the Rodman & Renshaw Techvest Global Healthcare Conference on Thursday, May 13, 2004 at 3:55 pm in London (10:55 am EDT). Dr. Gammans will provide an overview of Incara's latest progress, including the recent submission of the Investigational New Drug (IND) application to the Food and Drug Administration (FDA) for the use of AEOL 10150 to treat amyotrophic lateral sclerosis (ALS).
Interested investors can find a link to the live audio webcast from Incara's website at http://www.incara.com/ . An archived copy of the presentation will also be available at the same site.
ALS, the most common motor neuron disease, results from progressive degeneration of both upper and lower motor neurons and is usually fatal within 5 years. Unless there are questions from the FDA on the IND, Incara expects to begin dosing of the first volunteers for the Phase 1 clinical trials in the next 30-60 days. If the results of Phase 1 clinical trials are satisfactory, Incara's clinical plan calls for initiating a Phase 2/3 clinical trial of AEOL 10150 for treatment of ALS as early as the first half of 2005.
Incara Pharmaceuticals Corporation is developing a new class of small molecule catalytic antioxidants that destroy oxygen-derived free radicals, believed to be an important contributor to the pathogenesis of many diseases. Incara's catalytic antioxidants have been shown to reduce damage to tissue in animal studies of neurological disorders such as ALS and stroke, and in non- neurological indications such as cancer radiation therapy, chronic bronchitis and asthma.
The statements in this press release that are not purely statements of historical fact are forward-looking statements, and actual results might differ materially from those anticipated. These statements and other statements made elsewhere by Incara or its representatives, which are identified or qualified by words such as "intends," "likely," "will," "suggests," "expects," "might," "may," "believe," "could," "should," "would," "anticipates," "plans," or the negative of those terms or similar expressions, are based on a number of assumptions that are subject to risks and uncertainties. Important factors that could cause results to differ include risks associated with the uncertainties of scientific research, clinical trials and product development activities and the need to obtain funds for clinical trials and operations. These and other important risks are described in Incara's reports on Form 10-K, Form 10-Q and Form 8-K and its registration statements filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Incara assumes no obligation to update the information in this release.
Incara Pharmaceuticals Corporation